Placebo ID

DRUG2 trials

Sponsors

Anergis, Merck Sharp & Dohme LLC

Conditions

Allergic RhinitisAllergyCytomegalovirus Infections

Phase 1

Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen

TerminatedNCT01728519

AnergisAllergic Rhinitis, Allergy

Start: 2008-08-31End: 2012-07-31Updated: 2012-11-20

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

CompletedNCT01986010

Merck Sharp & Dohme LLCCytomegalovirus Infections

Start: 2013-11-25End: 2017-03-14Updated: 2021-11-01

Related Papers

A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.

2021-06-0224 citations

Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine

The Journal of Infectious Diseases2020-10-0110 citations

Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects

The Journal of Infectious Diseases2019-04-1171 citations